ESMO 2025: Final Efficacy Data and Biomarker Analysis from the Clear Cell Cohort of CALYPSO – UroToday
- ESMO 2025: Final Efficacy Data and Biomarker Analysis from the Clear Cell Cohort of CALYPSO UroToday
- ESMO 2025: Dual targeted therapy shows promise in previously treated advanced kidney cancer patients MD Anderson Cancer Center
- Dena Battle: Excited to Present Evidence-Based Data from KCCure at ESMO25 Oncodaily
- Vanderbilt’s new drug combo revolutionizes kidney cancer treatment WZTV
- ESMO 2025: Dual Targeted Therapy Demonstrates Potential in Treating Advanced Kidney Cancer After Prior Therapies Bioengineer.org